1. Erythropoietin and progression of CKD
F.H. Bahlmann, J.T. Kielstein, H. Haller, D. Fliser 
Kidney International 
Volume 72, Pages S21-S25 (November 2007)
DOI: /sj.ki
Copyright © 2007 International Society of Nephrology Terms and Conditions

2. Figure 1
Erythropoietin and nitric oxide bioavailibility. Effects of asymmetric dimethylarginine (ADMA; 3 mg/kg body weight) and rHuEPO (5000 U/kg body weight) alone or in combination (n=15 per group) on (a) glomerular filtration rate and (b) effective renal plasma flow in normotensive C57/Bl6 mice. Data are presented as changes from baseline, that is placebo injection. +P<0.05 vs baseline. #P<0.05 – rHuEPO vs ADMA injection.
Kidney International  , S21-S25DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions